DelixLabs

Peptides aren’t hype. They’re studied. Most people just never look deeper. delixlabs.com

@moneymurmur The compounding cliff is the underrated catalyst here. Once 503B bulk supply dries up, LLY recaptures pricing power on the entire weight-loss tail — not just net new scripts. LillyDirect's DTC pipe is the moat people aren't modeling.

Eli Lilly crushed earnings, hiked outlook. Zepbound/Mounjaro sales skyrocketing, 20k+ on Foundayo. FDA just blocked bulk compounding competitors. LLY has pricing power for 18+ months. Buy the dip if it hits today.

@breakoutchrts @SingularityRes Tirzepatide's the approved dual GIP/GLP-1 — VK2735 is Viking's dual agonist still in phase 2. Monthly SQ + oral tirz is the real moat story; that's what compresses compounding's runway.

@SingularityRes You need to do better research!Ozempic is a single GLP-1 agonist, VK2735 is more of a better dual agonist Zepbound,which will most likely be avail in biweekly and/or monthly SQ dosing & also oral delivery. Tirzepatide on pace for $50Billion/yr revs. Reta has more SEs, both are SQ

$VKTX HC Wainwright reiterates Buy & $102 PT

@LemonCooks 👀 something cooking

@DelixLabs Oooooooo

what are peptides and why are people taking them

@LombardTrucking @Clavicular0 lol

@DelixLabs @Clavicular0

No peptides, no “bonesmashing,” no TRT, no make up. @Clavicular0 could never

yeah the dose-response curve on PFS is genuinely terrifying because there isn't one. some people get it from a single dose, some run it for years and walk away clean. until we understand the AR conformational change + neurosteroid downstream effects, calling it dose-dependent is wishful thinking.

The dosage is irrelevant for many people who develop this. Some have reported full-blown PFS after taking less than 1 mg, even one time. These “screaming headlines” exist for a reason. This issue has been minimized and ignored for years while people have developed serious and permanent adverse reactions, leading to family breakdowns, job loss, financial devastation, and even suicide. This is also likely severely underreported, so I don’t think anyone can definitively reduce this to “1 to 2%” of users just yet. While it's true that many people seem to tolerate finasteride, people hear that and assume they’ll likely be fine, but the reality is someone is always the exception. And when they are, they’re met with the same talking points about how rare it is, as if their currently untreatable condition is somehow irrelevant. It’s time this is taken seriously without continuing to minimize the people who have been harmed.

Men have taken #Finasteride to help with hair loss for years, but new research is raising some serious concerns. The drug was linked to: ▪️Increased risk of anxiety ▪️Higher rates of depression ▪️Reports of suicidal thoughts in some users #HairLoss knowridge.com/2025/10/popula…

@GMarieSnickers @thegarybrecka tesa + ipa is a clean stack, the lipolysis synergy is real and you skip a lot of the GH-axis blowback. CJC adds pulse amplitude but it's not strictly necessary if sleep is dialed. how long are your cycles + are you running it AM fasted or PM?

@DelixLabs @thegarybrecka It sure does! I have never taken the dive into CJC but I have pinned Tesa and Ipa together in a cycle twice now and I have nothing but positive things to say about both peptides especially using them in unison.

My top starters for peptides: 1. BPC-157: Gut healing and tissue repair. Miracles for nicks, knees, shoulders. 2. TB-500: Pairs with BPC for injury recovery. 3. CJC-1295: Growth hormone releaser (stack with Ipamorelin). Boosts performance without shutting down your own production. How to start safe: - Work with a licensed clinician, don't grab random online stuff. - Cycle: 6 months steady, then 5 days on/2 off to avoid desensitization. - Delivery: injections, nasal sprays (NAD, BPC, TB500), or patches work well

@Go_H4M appreciate it. the gap between peptide bro-science and actual pharmacology is closing fast. takes people willing to read the papers instead of just the bottle.

@DelixLabs Nice to have the support of the scientific community in our conversations on peptides and their results!👍

Not all peptides work the same. And that’s the point. CJC-1295 supports sustained HGH release, while Ipamorelin mimics ghrelin to trigger your pituitary from a different pathway. Two signals. One outcome. More efficient, more consistent growth hormone production. That’s why the blend works so well. This is how optimization should be approached. Strategic. Layered. Built around your biology. 🌐Learn how we use peptides the right way at goh4m.com #peptides #hgh #biooptimization #longevity #performancehealth #hormones #trt #testosterone

the bottleneck isn't pharmacology, it's plumbing. glymphatic flow is mechanical, driven by CSF pulsation during slow-wave sleep + AQP4 channel polarization on astrocytes. you'd need a drug that opens the channels AND drives the pulsation AND replicates SWS neuronal silencing. nobody's close. closest thing right now is improving sleep quality, not replacing it.

@DelixLabs @Paul_Melman @captgouda24 Why is it impossible to imagine a drug that helps completing this process in an hour?

We need a crash effort to cure sleep. It’s appalling that we have to waste a third of our life insensate. If we were able to cut everyone’s sleep from 8 to 4 hours a night, this would be the equivalent of raising life expectancy from 80 to 100!

@longevityAC ty Annie. wall sits, split squat holds, and loaded carries are basically the whole over-40 lower body program. zero joint debt, full CNS recruitment. people skip them because they're boring, not because they don't work.

@DelixLabs Agree 💯💯💯

For my over 40 friends who are just starting an exercise routine: 1st, it's never too late to start. 2nd, wall sits are a great leg and core exercise to begin your fitness journey. Once you can hold a wall sit with knees at 90 degrees for one minute, try one of these variations!

fair concern but topical is mostly limited by molecular weight — anything >500 Da basically doesn't penetrate stratum corneum without a carrier. that's why most "topical peptide" products are signaling peptides for cosmetic skin (palmitoyl tetrapeptides etc), not the systemic ones. injectable BPC/TB-500/GHK have actual PK data, just less long-term human RCTs.

@lucristianx @DelixLabs I’m suspicious of injecting it… at least topical has been studied over time

what’s with the young men and peptides and protein and height and hair and botox and fillers and face over analysis

wegovy non-response is real — STEP trial data showed ~13-15% of people lost <5% body weight. usual suspects are GLP-1 receptor variants, fast baseline gastric emptying, or bile acid signaling differences. tirzepatide rescues a lot of sema non-responders because the GIP arm hits different pathways.

@DelixLabs @aathena10 Trend just means that’s what is in the common vernacular right now. Yes I was on wegovy. Didn’t do anything for me in terms of weight loss.

the seed oils discourse is 90% pattern-matching to ultra-processed food. the oil isn't doing what people think — the matrix it's bound to is. swap canola for tallow in a frozen dinner and you've still got a 600-calorie sodium bomb made of refined starch. the macro problem isn't the oil, it's the engineered hyperpalatability around it.

Why ingredient changes don’t always mean healthier food | Layne Norton, Ph.D. (@BioLayne) This clip is from episode # 380 of The Drive which was released on 1/19/26. In the full episode, we cover: -The core arguments against seed oils: the four main claims underlying the idea that seed oils are uniquely harmful, and how well they hold up once major confounders are addressed -The historical trials that shaped the debate: the Minnesota Coronary Experiment, Sydney Diet Heart Study, Rose Corn Oil trial, and later studies replacing saturated fat with polyunsaturated fat -Mechanisms and causality: LDL cholesterol, oxidized LDL, linoleic acid (omega-6), inflammation, -Mendelian randomization, and why lifetime LDL exposure matters more than per-particle oxidation risk -Practical takeaways: industrial processing concerns, cooking oils, real-world dietary fat choices, and how to prioritize nutrition relative to calories, activity, and overall lifestyle factors Listen (Ep. # 380) to the full episode on my website (peterattiamd.com/laynenorton4/) or your favorite podcast player.

the metformin-as-longevity-drug discourse needed this trial. for years the case rested on observational data in diabetics, where the comparator group is unhealthy by definition. when you actually run the controlled study in a healthier cohort, the longevity signal mostly evaporates. underwhelming for the geroscience field, but exactly the kind of null result the rest of the pipeline needs.

A closer look at the MET-PREVENT trial and what its null results reveal about aging interventions and trial design. Full article linked below. bit.ly/4tpASVs

the gap between 'interesting mechanism paper' and 'changes what you do tomorrow' is where most clinical translation dies. statins shifting the bile-acid pool and downstream microbiome composition is plausible and probably real, but the effect size on actual outcomes is buried by the LDL effect. ranking what changes practice vs what's just biology is the hard part.

A study linking statins, the microbiome, and blood sugar control doesn’t change clinical practice. Full article linked below. bit.ly/4k9CUom

the alternative-cause split in women is one of the most underdiagnosed problems in cardiology. SCAD, coronary vasospasm, MINOCA — standard angiograms miss them because they're not looking for plaque. women under 50 presenting with MI symptoms get sent home twice as often as men, and the imaging defaults are part of why.

Atherosclerosis is not the only possible cause of a heart attack (myocardial infarction), and women are more prone to alternative causes than men. A closer look at the data tells a different story. Full article linked below. bit.ly/3NDqdpF

exactly. 'peptides' is a structural class — chains of amino acids, mostly under 50. that's it. it tells you nothing about mechanism, target, or risk. people argue about 'peptides' the way they'd argue about 'small molecules.' the conversation needs the same precision pharma uses for chemotypes.

And first person to say “insulin is a peptide” that’s like saying “estrogen is a steroid”. Yes, but We all know what we’re talking about when we say “peptides”… or do we? More precise nomenclature definitely needed.

Given the immense interest in peptides and divergent views about peptides of various types, I assembled a small collection of experts that I’ll be talking to (separately) on the podcast. No matter what your stance is on peptides, it’s wise get educated! They are definitely here to stay!

the divergent views thing is real. 'peptides' covers everything from collagen powder to insulin to GHK-Cu. lumping them as one category is how you get bad takes from both sides. the GLP-1s, the healing peptides (BPC, TB-500), and the growth hormone secretagogues (sermorelin, ipamorelin) are three completely different risk/reward profiles.

the funding gap is the real problem. BPC is unpatentable as a 15-amino-acid sequence, so no big pharma sponsor wants to run a $20M phase 2 they can't recoup. only path forward is academic-led or patient-funded consortium trials. peptide research is structurally orphaned by the IP system.

Interpret this how you will, but I sure hope someone will do a proper BPC trial before long.

So many of my “conventional” (not in the health and wellness space or even online much) MD friends are asking about peptides to 1) get educated (patients are asking them about peptides) 2) they want to know if BPC can help their knee or shoulder or whatever. Wild.

this is the moment peptides cross from gym lore to clinic. BPC has the strongest mechanistic case in the rodent tendon/ligament literature — fibroblast migration, VEGF upregulation, vascular endothelial repair. the human data is mostly anecdotal but it's piling up faster than the trial pipeline. clinicians needing to learn this from patients tells you where the gap is.

the shingles vaccine longevity data is one of the more interesting recent findings — a Welsh natural-experiment study showed ~20% reduction in dementia incidence over 7 years for people who got it. mechanism is unclear (immune modulation? VZV reactivation suppression?), but the effect size is hard to ignore. underrated longevity move.

I'm getting two vaccines next week: Tdap and shingles. The Tdap because Kate's family has a newborn and we're visiting. Shingles for the potential longevity benefits. Data we're looking at: 1. Lower Alzheimer risk with vaccination in 1.6 million people, 8 year follow up, age 65+ + Tdap/Td: 30% lower relative risk + Shingles: 25% lower + Pneumococcal: 27% lower 2. Slower biological aging from shingles vaccination in 3,884 people, age 70+ Modest but significant improvements in inflammation, epigenetic and transcriptomic aging, and composite biological age. Molecular signals strongest within 3 years; inflammation benefits emerged later. 3. Better outcomes after breakthrough shingles in 38,092 people, age 50+, median 3.6y follow up In adults who developed shingles, prior vaccination was linked to: + 41% lower all-cause mortality + 21% lower MACE (MI, stroke, PE, sudden cardiac death) + 16% lower dementia risk Note: all three studies are observational. They show association, not causation. A randomized controlled trial on longevity outcomes is not feasible here as you can't randomize people to skip vaccines for years. The signal is consistent across independent large cohorts, which strengthens confidence, but the possibility of healthy vaccine bias exists in all three. People who stay current on vaccines tend to have better health behaviors overall. I find the mechanistic case for shingles specifically compelling. VZV reactivation drives neuro inflammation, and vaccination appears to blunt that cascade which is why we weight this evidence more heavily than the numbers alone.